Search

Your search keyword '"Verbesselt, R."' showing total 298 results
Start Over Author "Verbesselt, R."
298 results on '"Verbesselt, R."'

18. Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period

Author

Kulo, A. (Aida), Smits, A., Maleškić, S. (Sanita), Velde, M. (Marc) van de, Calsteren, K. (Kristel) van, de Hoon, J. (Jan), Verbesselt, R. (Rene), Deprest, J., Allegaert, K.M. (Karel), Kulo, A. (Aida), Smits, A., Maleškić, S. (Sanita), Velde, M. (Marc) van de, Calsteren, K. (Kristel) van, de Hoon, J. (Jan), Verbesselt, R. (Rene), Deprest, J., and Allegaert, K.M. (Karel)

Abstract

Racemic ketorolac clearance (CL) is significantly higher at delivery, but S-ketorolac disposition determines the analgesic effects. The aim of this study was to investigate the effect of pregnancy and postpartum period on enantiomer-specific (S and R) intravenous (IV) ketorolac pharmacokinetics (PKs). Data in women shortly following cesarean delivery (n=39) were pooled with data in a subgroup of these women that was reevaluated in the later postpartum period (postpartum group, n=8/39) and with eight healthy female volunteers. All women received single IV bolus of 30 mg ketorolac tromethamine. Five plasma samples were collected at 1, 2, 4, 6, and 8 hours and plasma concentrations were determined using high performance liquid chromatography. Enantiomer-specific PKs were calculated using PKSolver. Unpaired analysis showed that distribution volume at steady state (Vss, L/kg) for S- and R-ketorolac was significantly higher in women shortly following cesarean delivery (n=31) compared to postpartum group (n=8) or to healthy female volunteers (n=8). CL, CL to body weight, and CL to body surface area (CL/BSA) for S- and R

Published
2017
Full Text
View/download PDF

19. Propofol in neonates

Author

Vanderhaegen, J., Naulaers, G., Verbesselt, R., and karel allegaert

Subjects
lcsh:RD78.3-87.3, lcsh:Pharmacy and materia medica, Anesthesiology and Pain Medicine, lcsh:Anesthesiology, lcsh:RS1-441, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics
Published
2010

22. Abstracts of papers clinical pharmacological meeting

Author

Merkus, F. W. H. M., Gribnau, F. W. J., Thien, Th., Louwerenburg, Hans W., Kingma, J. Herre, van Gilst, Wiek H., Six, A. Jacob, de Graeff, Pieter, Wesseling, Harry, BoeLaert, J. R., Schurgers, M. L., Matthys, E. G., Belpaire, F., Daneels, R. F., de Cre, M. J., Boqaert, M. G., D'Haese, P. C., Verpooten, G. A., Lamberts, L. V., Liang, L., de Broe, M. E., de Meijer, P. H. E. M., Russel, F. G. M., Russel, A. J. M., van Ginneken, C. A. M., van Liedekerke, B. M., Lambert, W. E., Yousouf, M. A., de Roose, J. E., de Leenheer, A. P., Lambert, W., de Bersaques, J., Vanneste, L., de Leenheer, A., de Marie, S., Slaghuis, G., Rozing, P. M., Mattie, H., Poelma, F. G. J., Hilbers, H. W., Jansen, A. C. A., Tukker, J. J., Augusti, Jr, P., Verbeke, N., van Peer, A., Snoeck, E., Heykants, J., Bruynseels, J., Peeters, J., Amery, W., Rogiers, V., Vandenberghe, Y., Comet, M., Callaerts, A., Sonck, W., Guillouzo, A., Vercruysse, A., van Rooy, P., Rombaut, N., vanden Bussche, G., Tan, A. C. I. T. L., Jansen, T. L. Th. A., Termond, E. F. S., Kloppenborg, P. W. C., Thien, Th., Benraad, Th. J., van de Velde, V., Woestenbprghs, R., Hermens, W. A. J. J., Romeijn, S. G., Deurloo, M. J. M., Merkus, F. W. H. M., Musch, G., Massart, D. L., van Hengstum, M., Festen, J., van den Broek, W., Corstens, F., Beurskens, C., Hankel, M., de Smet, M., van Belle, S. J. P., de May, J., Storme, G. A., Kuppen, P. J. K., Schuitemaker, H., Veer, L. J. van't, van Oosterom, A. T., Schrier, P. I., de Bruijn, E. A., de Pooter, C. H., Tjaden, U. R., van Slooten, H., Roelevink, H. P., Smit, E., de Vries, E. G. E., Ijmker, J., Uges, D. R. A., Moors, M., Mertens, K., van Hecken, A., de Lepeleire, I., Verbesselt, R., Tjandra-Maga, T. B., de Schepper, P. J., Guelen, P. J. M., Jansen, T. J., Vrijhof, W. P., de Vos, D., Scharpé, S., Verkerk, R., Lsmeire, N., Zijlstra, I. F., Gribnau, F. W. J., Haaijer-Ruskamp, F. M., Post, D., Reddingius, P. F., Wesseling, H., Wollersheim, H. C. H., van den Meiracker, A. H., Veld, A. J. Man in 't, Admiraal, P., Boomsma, F., Derkx, F., Schalekamp, M. A. D. H., Schoors, D. F., Dupont, A. G., Claessen, F., Reljenga, J., Lenders, J. W. M., Thlen, Th., Laekeman, G., Muylle, L., van Hoydonck, A., Herman, A. G., and Peetermans, M. E.

Published
1988
Full Text
View/download PDF

25. Abstracts of papers

Author

Belpaire, F., Derkx, F. H. M., Bryson, S. M., Kelman, A. W., Whiting, B., Modderman, E. S. M., Merkus, F. W. H. M., Hilbers, H. W., Zuidema, J., Raai jmakers, J. A. M., Terpstra, G. K., Wassink, G. A., Kreukniet, J., Tjandramaga, T. B., Verbesselt, R., van Hecken, A., Mullie, A., de Schepper, P. J., van Hooff, M. E. J., van Baak, M. A., Rahn, K. H., Colardyn, F., Clement, D., van Riel, P. L. C. M., van de Putte, L. B. A., Gribnau, F. W. J., HacRae, K. P., Vree, T. B., Hekster, C. A., Verpooten, G. A., Buntinckx, A. P., Verbist, L., de Broe, M. E., Vincent, H. H., Boomsma, F., Schalekamp, M. A. D. H., van de Donk, H. J. M., Duchateau, G. S. M. J. E., Paulus, G. J., Roels, F., Tulkens, P., Winograd, B., Oosterbaan, M. J. M., Boerema, H., van der Kleijn, E., Monbaliu, J., Tukker, J. J., de Blaey, C. J., van Peer, A., Woestenborghs, R., Heykants, J., Verlinden, M., Reyntjens, A., Dirks, R. J. M., Hallynck, Th., Pijck, J., Soep, H., Lagas, M., and Jonkman, J. H. G.

Published
1983
Full Text
View/download PDF

26. Postmenstrual age and CYP2D6 polymorphisms determine tramadol O-demethylation in critically I11 neonates and infants

Author

Allegaert, Karel, van Schaik, Ron, Vermeersch, S, Verbesselt, R, Cossey, V, Vanhole, C, Fessem, Mariane, de Hoon, J, van den Anker, John, and Clinical Chemistry

Abstract

To document determinants of O-demethylation in critically ill (pre)term neonates and infants, tramadol (M) and O-demethyl tramadol (M1) concentrations were quantified in eighty-six 24 h urine collections and 168 plasma samples. A significant correlation of urine log M/M1 (0.98, SD 0.66) and plasma log M/M1 (0.78, SD 0.45) with postmenstrual age (PMA) (r = -0.69 and -0.65) was observed. One-way analysis of variance documented a significant decrease in urine log and plasma log M/M1 with increasing CYP2D6 activity score (F value 11.6 and 22.55). PMA and CYP2D6 activity score determined the urine and plasma log M/M1 (R-2 0.59 and 0.64) in a forward multiple regression model. We therefore conclude that PMA and CYP2D6 polymorphisms determined O-demethylation activity in (pre)term neonates and young infants, illustrating the impact of pharmacogenetics on drug metabolism in neonates although a relevant part of the interindividual varaibility remained unexplained. Besides compound-specific relevance, CYP2D6 iso-enzyme specific data on in vivo ontogeny of O-demethylation can contribute to safer and more effective administration of drugs metabolized by the same route in this population.

Published
2008

31. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study.

Author

Calsteren, K. van, Verbesselt, R., Ottevanger, N., Halaska, M., Heyns, L., Bree, R. de, Bruijn, E. de, Chai, D., Delforge, M., Noens, L., Renard, V., Witteveen, E., Rob, L., Hoon, J. de, Amant, F., Calsteren, K. van, Verbesselt, R., Ottevanger, N., Halaska, M., Heyns, L., Bree, R. de, Bruijn, E. de, Chai, D., Delforge, M., Noens, L., Renard, V., Witteveen, E., Rob, L., Hoon, J. de, and Amant, F.

Abstract

1 oktober 2010, Contains fulltext : 89768.pdf (publisher's version ) (Closed access), OBJECTIVE: To determine the impact of physiologic changes of pregnancy on pharmacokinetics of chemotherapeutic agents. DESIGN: A preclinical and a clinical case-control trial. SETTING: Institute of Primate Research Nairobi and collaborating hospitals in Belgium, the Netherlands and Czech Republic. POPULATION: Pregnant and nonpregnant women and baboons receiving chemotherapy. METHODS: Chemotherapy pharmacokinetics was compared between the pregnant and nonpregnant state. Standard-dosed chemotherapy regimens were administered in pregnant and nonpregnant baboons/women, followed by serial blood samplings. Drug plasma levels were determined using high performance liquid chromatography and atomic absorption spectrometry. MAIN OUTCOME MEASURES: Area under the curve (AUC), maximal plasma concentration, terminal elimination half-life, clearance and distribution volume of each drug in pregnant and nonpregnant state. RESULTS: Intraindividual comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in three and two baboons, respectively. In the clinical trial, two patients were exposed to doxorubicin and one patient was exposed to paclitaxel/platinum during and after pregnancy. Furthermore, a pooled analysis was performed based on 16 cycles of pregnant and 11 cycles of nonpregnant women. Numbers of pregnant/nonpregnant patients were 5/2, 7/5, 4/4 and 2/2 for paclitaxel, doxorubicin, epirubicin and platinum, respectively. For all drugs tested in the preclinical and clinical study, a decreased AUC and maximal plasma concentration and an increased distribution volume and clearance were observed in pregnancy. CONCLUSIONS: Although numbers were too small for statistical significance, pregnancy-associated physiologic alterations appear to lead to a decrease in plasma exposure of chemotherapeutic drugs. The importance of long-term follow-up of women treated with chemotherapy during pregnancy is underscored.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results